Last reviewed · How we verify

NCT06127810

MRI Gadopiclenol Enhanced Imaging of CNS Tumors

Withdrawn Last updated 4 February 2025
What this trial tests

trial testing CE MRI on 0.064T Scanner in Image. Withdrawn.

Timeline
30 December 2024
Primary endpoint
30 December 2024
30 December 2024

Quick facts

Lead sponsorMedical University of South Carolina
StatusWithdrawn
Study typeOBSERVATIONAL
Start date30 December 2024
Primary completion30 December 2024
Estimated completion30 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of South Carolina

Who can join

18 and older, any sex, with Image. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this pilot study is to compare a standard of care MRI scan to a non-standard of care MR imaging with portable (0.064 Tesla) MRI following the administration of non-SOC contrast called Gadopiclenol on 10 subjects with known brain tumors. Participants will be randomized to receive either standard MRI or portable MRI first following contrast injection

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Image

Currently open trials in the same condition.

Other Medical University of South Carolina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06127810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing